stick
joint survey consum show purchas over-the-counter product prepar
privat label higher total unit typic recent
nielsen data show gain cough-cold pain segment rais
ep key question whether drive structur chang
adopt benefit new wild card over-the-counter drug reform provis
stimulu bill
proprietari survey consum indic larg uptick over-the-counter purchas
earli stage outbreak privat label purchas larger percentag
total recent surg over-the-counter drug sale latest nielsen data confirmatori
joint project consum health care team jefferi survey
individu repres gender household incom geograph dispers see
survey over-the-counter healthcar trend consum respons ascertain
extent outbreak consum behavior particularli relat
purchas over-the-counter product survey look sever categori includ cough/
cold/flu gi analges find includ respond purchas over-the-counter
product prepar importantli indic someon
household experienc flu like symptom good portion increas
like non covid relat jibe recent cdc info us experienc
unusu late-season surg influenza-lik ill privat label unit
track store brand share consum note purchas
reflect incom rather perceiv valu posit favor store brand
underscor recent bimonthli nielsen data week end march
show y/i increas upper respiratori otc increas analges
calcul addit rev prolong us flu
season howev ep upsid impact modest recent uptick flu like
symptom us cdc surveil retail stock out given panic buy
project addit ww upper respiratori rev increas
eu time given countrywid quarantin
mani eu countri management note dampen consumpt hygien healthi
lifestyl segment weigh-loss drug repres chci rev
lower contribut key eu segment base recent
consum segment oper margin rang increas ep estimate
tabl key assumpt point
assum upsid outyear forecast ep estim increas
reflect recent sector multipl contract new pt vs base
vs previous ep estimate unchang
financi restat reflect divestitur tysabri
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
financi restat reflect divestitur tysabri
chca busi grow low single-digit rate driven
new product flow nexium nasonex over-the-counter launch
expect
chci margin continu steadili expand
meaning growth d/new product success
develop self busi
chc segment realiz stronger anticip net
cost save restructur
litig win potenti earlier expect
chci return growth faster expect
gener price environ continu neg
chci remain drag prgo busi
lower anticip gross margin expans due
vertic
compani develop manufactur distribut
over-the-count over-the-counter healthcar product gener
rx drug co largest global manufactur
infant formula benefit signific
macro trend consum accept store
brand omega brand european over-the-counter busi
met expect plan separ
divest spin etc gener busi uncertain
unlock valu sharehold recent
emerg legaci tax liabil also concern
potenti extern pressur sharehold
activ take-over specul
new product launch chc busi rx
potenti bolt-on acquisit chc self
success p-iv challeng larg brand rx product
pleas see import disclosur inform page report
chart share revenu top segment us eu
chart estim revenu impact
chart ep sensit analysi
outlook cross current pass stimulu packag includ over-the-counter
transform effort new management team posit requir invest
could take time play meantim half recent us consum
growth come ranir acquisit tuck-in look way
help fill void potenti help natur launch next year gener
rx side proair launch help potenti over-the-counter voltaren gel introduct
comp look difficult post loss g-androgel exclus last quarter final long-
await over-the-counter reform bill appar includ stimulu bill prior version
bill estim could bring user fee add employe fda
over-the-counter oversight understand larg focus improv safeti howev ad
pleas see import disclosur inform page report
firepow could possibl lead rx over-the-counter switch end
dearth switch recent year post larg gain ppi allergi drug
hurt prgo new product flow extent could expedit switch
prior commission gottlieb favor could potenti posit develop
bear watch
pleas see import disclosur inform page report
pleas see import disclosur inform page report
